Castle Biosciences, Inc.

Castle Biosciences, Inc. is a molecular diagnostics company that provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. Its portfolio includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test for predicting progression to high-grade dysplasia or esophageal cancer in BE patients; AdvanceAD-Tx, a non-invasive GEP test to guide systemic treatment selection for moderate-to-severe AD; DecisionDx-SCC for cutaneous squamous cell carcinoma; MyPath Melanoma for diagnosing difficult melanocytic lesions; and DecisionDx-UM for uveal melanoma risk stratification. The company markets its products to dermatology and gastroenterology markets.

Castle Biosciences, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CSTL. Its financials are reported in US Dollars (USD), as the company is headquartered in the United States and operates primarily in the US market.

Castle Biosciences operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company focuses on developing and commercializing diagnostic tests and research tools to aid in disease detection, risk assessment, and treatment guidance, particularly in oncology and dermatology.

Castle Biosciences, Inc. is headquartered in Friendswood, Texas, United States. The company serves the dermatology and gastroenterology markets, offering its diagnostic tests to healthcare providers for conditions such as melanoma, cutaneous squamous cell carcinoma, uveal melanoma, Barrett's esophagus, and atopic dermatitis. Its products are primarily marketed in the United States.

Castle Biosciences offers a range of molecular diagnostic tests. Key products include DecisionDx-Melanoma, a GEP test for risk stratification in invasive cutaneous melanoma; TissueCypher, a spatialomics test for Barrett's esophagus risk assessment; AdvanceAD-Tx, a non-invasive GEP test guiding systemic treatment for moderate-to-severe atopic dermatitis; DecisionDx-SCC for cutaneous squamous cell carcinoma; MyPath Melanoma for diagnosing ambiguous melanocytic lesions; and DecisionDx-UM for uveal melanoma metastasis risk. These tests help clinicians make more informed decisions about patient management and treatment.